arrow
A

Alessio Cirillo

Sapienza University
H指数:9
被引数:422

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Circulating CD137⁺Treg cells and LOX-1⁺PMN-MDSCs as biomarkers of immunotherapy resistance in (R/M) HNSCC patients

外周CD137⁺Treg细胞和LOX-1⁺PMN-MDSCs作为免疫治疗耐药的(R/M)HNSCC患者的生物标志物

2025-12-030
OAAI
Retrospective Trial on Cetuximab Plus Radiotherapy in Elderly Patients with Head and Neck Squamous Cell Cancer

头颈鳞状细胞癌老年患者西妥昔单抗联合放疗的回顾性试验

2025-11-020
OAAI
Process management method in head and neck cancer patient care

头颈癌患者护理中的流程管理方法

2025-05-230
OA
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study (vol 10, 58, 2024)

药物-药物相互作用对abemaciclib在AB-意大利研究的真实世界经验中的临床影响 (第10卷,58卷,2024)

2024-08-020
OAAI
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study

在AB-意大利研究的现实世界经验中,药物-药物相互作用对abemaciclib的临床影响

2024-07-173
OAAI
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis (vol 24, 430, 2024)

基于Pembrolizumab的一线治疗PD-L1-positive,复发或转移性头颈部鳞状细胞癌: 回顾性分析 (第24卷,430,2024)

2024-04-170
OAAI
Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort

抗核抗体可预测免疫检查点抑制剂治疗的无症状患者免疫相关不良事件的发展: 来自单中心队列的结果

2024-04-100
OAAI
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis

基于派姆单抗一线治疗PD-L1-positive、复发或转移性头颈部鳞状细胞癌的回顾性分析

2024-04-081
OAAI
Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study

接受靶向治疗的晚期乳腺癌患者接受第三剂SARS-CoV-2 mRNA-BNT162b2疫苗后的免疫反应和临床结局: 一项前瞻性研究

2023-11-071
OAAI
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy

免疫谱在预测免疫治疗癌症患者预后中的作用

2022-11-0315
OAAI
Genomic and Immune Approach in Platinum Refractory HPV-Negative Head and Neck Squamous Cell Carcinoma Patients Treated with Immunotherapy: A Novel Combined Profile
2022-10-283
OAAI
Dental Implant Failure Risk in Post Oncological Patients, a Retrospective Study and Sapienza Head and Neck Unit Decisional Protocol- 7 Years of Follow-Up
2022-08-020
OAAI
Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario

化疗或免疫检查点抑制剂治疗的转移性非小细胞肺癌患者的肾功能结局: 意外情况

2022-04-246
OAAI
The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature

CDK4/6抑制剂Ribociclib在局部晚期和寡转移性激素受体阳性,Her2阴性,晚期乳腺癌中的作用: 病例系列和文献复习

2022-02-092
OAAI
Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era
2021-07-122
OAAI